Abstract

Case Series

Pure Red Cell Aplasia - Post Major ABO Incompatible Allogenic Stem Cell Transplantation Role of Ibrutinib

Ranjit Kumar CS*, Anil Aribandi, Chaitanya GB and Venkata Ravi Kiran D

Published: 24 July, 2024 | Volume 8 - Issue 1 | Pages: 038-041

Pure Red Cell Aplasia (PRCA) is a well-recognized complication of Major ABO-incompatible allogeneic stem cell transplantation. It is featured by anemia, Reticulocytopenia, and the absence of erythroblasts in a normal-appearing bone marrow biopsy. The mechanism for PRCA is presumed to be the persistence of recipient isoagglutinins, produced by residual host B lymphocytes or plasma cells, which probably interfere with the engraftment of donor erythroid cells. Several risk factors for PRCA have been reported, such as the presence of Anti-A Isoagglutininsbefore transplantation, reduced intensity conditioning, absence of Graft Versus Host Disease (GVHD), sibling donor and Cyclosporin A(CsA) as GVHD prophylaxis. PRCA is not a barrier to going ahead with Hematopoietic Stem Cell Transplantation (HSCT). There are many therapeutic options however few recover spontaneously, among the available options include high-dose steroids, Erythropoietin(EPO), Plasma exchange, Donor lymphocyte Infusion (DLI), treatment with Rituximab, Bortezomib, Daratumumab and tapering or discontinuation of immunosuppression. All these options have variable success in the literature ranging from 30% - 70%, Non-responders become red cell transfusion dependent and their quality of life is impaired. We are reporting a novel therapeutic option, Ibrutinib as an armamentarium in treating the PRCA post-HSCT, which works by blocking the Bruton Tyrosine Kinase (BTK) pathway thereby inhibiting the host B cell isoagglutinins production and good clinical response.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001041 Cite this Article Read Full Article PDF

Keywords:

PRCA; Ibrutinib; ABO mismatch transplant; EPO; BTK inhibitor

References

  1. Gao Y, Gao F, Shi J, Fu H, Huang H, Zhao Y. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation. J Zhejiang Univ Sci B. 2021;22(8):695-700. Available from: https://doi.org/10.1631/jzus.b2000532
  2. Henig I, Yehudai-Ofir D, Zohar Y, Zuckerman T. Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment. Acta Haematol. 2021;144(6):683-687. Available from: https://doi.org/10.1159/000515257
  3. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, et al. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016;22(5):961-965. Available from: https://doi.org/10.1016/j.bbmt.2016.02.008
  4. Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019;94(8):E216-E219. Available from: https://doi.org/10.1002/ajh.25515
  5. Griffith LM, McCoy JP Jr, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128(5):668-675. Available from: https://doi.org/10.1111/j.1365-2141.2005.05364.x
  6. Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, et al. GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11(12):1006-1013. Available from: https://doi.org/10.1016/j.bbmt.2005.07.015
  7. Arslan S, Stein AS, Forman SJ, Nakamura R, Malki MMA. Ibrutinib for Pure Red Cell Aplasia after Allogeneic Hematopoietic Stem Cell Transplant with Major ABO Incompatibility. Biol Blood Marrow Transplant. 2020 Mar 1;26(3):S362-S363. Available from: https://doi.org/10.1016/j.bbmt.2019.12.195
  8. Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, et al. PRCA Collaborative Study Group. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19(7):1026-32. Available from: https://doi.org/10.1016/j.bbmt.2013.04.004
  9. Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. N Engl J Med. 2018;379(19):1846-1850. Erratum in: N Engl J Med. 2019;380(3):302. Available from: https://doi.org/10.1056/nejmoa1807438
  10. Arslan S, Ali H, Mei M, Marcucci G, Forman S, Nakamura R, et al. Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transplant. 2022;57(5):830-833. Available from: https://doi.org/10.1038/s41409-022-01590-0
  11. Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Glob Oncol. 2020;6:GO.20.00012. Available from: https://doi.org/10.1200/GO.20.00012
  12. Ranjit Kumar Kumar CS, MD; Harshitha Aribandi. PRCA post allogenic transplant-Ibrutinib induced periungal granuloma 1. 2022. Available from: https://imagebank.hematology.org/imageset/60368/ibrunib-induced-periungal-granuloma

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?